Table 1.
Clinicopathological characteristics of the HER2+ cohort
| Characteristic | N° patients | % | Median | Range |
|---|---|---|---|---|
| Total number of patients | 86 | |||
| Age (years) | 50 | 25–79 | ||
| Length follow-up (months) | 30 | 6–112 | ||
| Menopausal status | ||||
| Pre | 48 | 55.8 | ||
| Post | 38 | 44.2 | ||
| Tumor size | ||||
| T1 | 33 | 38.8 | ||
| T2 | 36 | 42.4 | ||
| T3 | 12 | 14.1 | ||
| T4 | 4 | 4.7 | ||
| Not documented | 1 | |||
| Lymph node status | ||||
| N0 | 44 | 51.2 | ||
| N1 | 30 | 34.9 | ||
| N2 | 5 | 5.8 | ||
| N3 | 7 | 8.1 | ||
| Clinical stage | ||||
| I | 25 | 29.1 | ||
| II | 40 | 46.5 | ||
| III | 21 | 24.4 | ||
| Histological grade | ||||
| 1 | 7 | 8.9 | ||
| 2 | 28 | 35.4 | ||
| 3 | 44 | 55.7 | ||
| Not documented | 7 | |||
| Estrogen receptor positive | 66.3 | |||
| Progesterone receptor positive | 55.8 | |||